dsRNA reagents that can be used as negative controls and their applications

By designing dsRNA reagents with nucleotide sequence differences of no more than 3, the off-target phenomenon of siRNA reagents was solved, achieving a negative control effect in RNAi reagent research, ensuring experimental accuracy and reducing non-specific interference.

CN123063397APending Publication Date: 2026-11-10NANJING GENSCRIPT BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610611573.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing siRNA reagents are prone to off-target effects in research, and there is a lack of a unified method to reduce the risk of off-target effects, leading to inaccurate experimental results and the presence of interfering factors. There is a need to develop scramble siRNA sequences that have very low off-target effects as negative controls.

Method used

A dsRNA reagent is provided, which contains a sense strand and an antisense strand, with a nucleotide sequence difference of no more than 3, forming a double-stranded region of 19-30 nucleotide pairs in length, to reduce off-target effects and serve as a negative control for RNAi reagents.

Benefits of technology

Off-target effects are extremely rare, making it suitable as a negative control group in RNAi reagent research, ensuring the scientific rigor and accuracy of experiments, and reducing non-specific interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_47
    Figure SMS_47
  • Figure SMS_48
    Figure SMS_48
  • Figure SMS_49
    Figure SMS_49
Patent Text Reader

Abstract

This invention relates to the field of small nucleic acids, specifically to dsRNA reagents that can be used as negative controls and their applications. This invention yields scramble sequences with minimal off-target effects, which can be used as negative control groups for screening assays of any target RNAi reagent (such as siRNA).
Need to check novelty before this filing date? Find Prior Art

Description

Cross-reference to related applications

[0001] This invention claims priority to Chinese Patent Application No. 2025105852256, filed on May 7, 2025, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to the field of small nucleic acids, and more specifically, to dsRNA reagents that can be used as negative controls and their applications. Background Technology

[0003] RNA interference (RNA interference) is a widespread and evolutionarily conserved biological mechanism that plays a crucial role in disease treatment and diagnosis. RNA interference is essentially triggered by small RNA fragments (sRNAs) induced by double-stranded RNA (dsRNA). First discovered in *Escherichia coli* in 1984, sRNAs reduce the expression of target genes by decreasing translation efficiency or promoting mRNA degradation. sRNAs are widely distributed in the biological world and, based on their synthesis mechanisms, can be classified into siRNA, miRNA, piRNA, tRFs, etc. sRNAs can bind to proteins such as ribonuclease AGO and related accessory molecules to form the RISC complex. Guided by the sRNA, this complex can target and cleave target transcripts that are anticomplementary to the sRNA, thereby inhibiting the target gene. The mechanisms of action also differ among different types of sRNAs. When siRNA mediates gene silencing, it needs to be highly matched with the target sequence; while miRNA does not need to be perfectly matched with the target sequence to exert its effect. It only needs the seed region to be complementary to the target sequence to induce RNA-mediated gene silencing.

[0004] Because siRNA can target any transcribed gene or fragment and has a short development cycle, it has become an important drug development material in the market. Currently, several small nucleic acid-based drugs are on the market, and many more are undergoing clinical trials. However, a significant drawback of siRNA is its susceptibility to off-target effects. siRNA-mediated off-target effects mainly include two levels: 1) off-target effects caused by the homology / similarity of the sequence itself; and 2) immune-related side effects triggered after exogenous nucleic acids are transfected into cells. The mechanisms of off-target effects can be divided into two categories: Category I, where highly homologous sequences easily induce off-target effects; and Category II, miRNA-like off-target effects. Because miRNAs do not need to perfectly match the target sequence to exert their effects, only that the seed region is complementary to the target sequence, miRNAs can simultaneously target multiple regions, easily leading to off-target effects (Neumeier & Meister, 2021). A growing body of research indicates that siRNAs can also induce off-target effects—siRNAs can bind to the 3' untranslated region of mRNAs through partial complementarity, thereby inhibiting the expression of multiple target genes (Seok et al., 2018). Therefore, both candidate siRNAs under investigation and scramble siRNA sequences used as control groups in experiments need to be designed to minimize the risk of off-target effects. Although many studies have shown that chemical modifications can reduce off-target effects, there is currently no universally accepted method to reduce off-target levels. Therefore, developing scramble siRNA sequences that do not exhibit any off-target effects is extremely challenging.

[0005] When studying siRNA function, a negative control group, i.e., a scrambled siRNA sequence, is typically required to clarify the specific targeting effect of the target siRNA, eliminate interfering factors in the experiment, verify the accuracy of experimental procedures, assess background signals, and ensure the scientific rigor of the experiment. Scrambled siRNA sequences consist of short double-stranded nucleotides, which can easily induce off-target effects. However, as a negative control for siRNA experiments, the scrambled siRNA must strictly ensure that it has no knockdown effect on either the target or non-target genes. Therefore, screening for more suitable control sequences is particularly important to more accurately assess the specific effect of siRNA and eliminate non-specific interference. Summary of the Invention

[0006] The first objective of this invention is to provide a dsRNA reagent comprising a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand contains at least 15 consecutive nucleotides that differ from the sequence shown in any one of SEQ ID No. 1, 2, 6 by no more than 3 nucleotides; and the sense strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.

[0007] As a preferred embodiment, the positive strand contains at least 15 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 7, 8, or 12 by no more than 3 nucleotides.

[0008] As a preferred embodiment, the sense strand contains at least 16, 17, 18, 19 or 20 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 7, 8 or 12 by no more than 3 nucleotides, and the antisense strand contains at least 16, 17, 18, 19 or 20 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 1, 2 or 6 by no more than 3 nucleotides.

[0009] As a preferred embodiment, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 7 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 1 by 0, 1, or 2 nucleotides.

[0010] As a preferred embodiment, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 8 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 2 by 0, 1, or 2 nucleotides.

[0011] As a preferred embodiment, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 12 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 6 by 0, 1, or 2 nucleotides.

[0012] As a further preferred embodiment, the nucleotide sequence of the sense strand is shown in SEQ ID No. 7, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 1.

[0013] As a further preferred embodiment, the nucleotide sequence of the sense strand is shown in SEQ ID No. 8, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 2.

[0014] As a further preferred embodiment, the nucleotide sequence of the sense strand is shown in SEQ ID No. 12, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 6.

[0015] As a preferred embodiment, the nucleotides in the dsRNA reagent are each independently unmodified or modified nucleotides; The modified nucleotides include one or more of the following: deoxynucleotides, 3'-terminal deoxythymidine (dT) nucleotides, 2'-terminal deoxythymidine (dT) nucleotides, etc. O Methyl-modified nucleotides, 2' Fluorine-modified nucleotides, 2' Deoxy-modified nucleotides, locked nucleotides, unlocked nucleotides, conformation-restricted nucleotides, constrained ethyl nucleotides, base-free nucleotides, 2' Amino-modified nucleotides, 2' O Allyl-modified nucleotides, 2' C Alkyl-modified nucleotides, 2' Hydroxyl-modified nucleotides, 2' Methoxyethyl modified nucleotides, 2' O Alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, non-natural bases including nucleotides, tetrahydropyran-modified nucleotides, 1,5 Nucleotides modified with dehydrated hexitol, nucleotides modified with cyclohexenyl, nucleotides including phosphate thioester groups, nucleotides including methylphosphonate groups, and nucleotides including 5'- Phosphate esters of nucleotides, including 5' Phosphate ester mimicry nucleotides, heat-labile nucleotides, ethylene glycol-modified nucleotides (GNA), nucleotides including 2' phosphate esters, and 2' phosphate esters. O (N Nucleotides modified with methylacetamide.

[0016] As a preferred embodiment, the length of the double-stranded region is 19 to 30 nucleotide pairs.

[0017] As a further preferred embodiment, the length of the double-stranded region is 19 to 23 nucleotide pairs.

[0018] As a further preferred embodiment, the length of the double-stranded region is 21 nucleotide pairs.

[0019] As a preferred embodiment, at least one of the sense strand and the antisense strand is connected to one or more ligands selected from the following: lectins, glycoproteins, lipids, nucleic acid aptamers, polymers, polypeptides, proteins, lipophilic molecules, polysaccharide molecules, vitamins, antibodies or antibody fragments, photosensitive oligonucleotides, lipid nanoparticles, exosomes, metal nanoparticles, polymer nanoparticles, viral vectors, and haptens.

[0020] As a further preferred embodiment, the ligand is selected from one or more of the following: N Acetylgalactosamine or its derivatives, lipid nanoparticles, RGD peptides or their analogs, TfR antibodies, nucleic acid aptamers, folic acid, transferrin, ionizable lipids, cholesterol or its derivatives, polygalactose, and polylactose.

[0021] The present invention further provides a cell containing the dsRNA reagent described above.

[0022] The present invention further provides a composition comprising the dsRNA reagent and a pharmaceutically acceptable carrier.

[0023] The present invention further provides a kit containing the dsRNA reagent, the cells, or the composition described herein.

[0024] The present invention further provides the application of the dsRNA reagent, the cells, or the composition described herein as a negative control in the field of RNA interference.

[0025] The present invention further provides the application of the dsRNA reagent, the cells, the composition, or the kit in the detection of the efficacy of RNAi reagents, wherein the dsRNA reagent, the cells, or the composition are used as negative controls.

[0026] That is, the present invention also provides a method for detecting the efficacy of an RNAi reagent, the method comprising: using the dsRNA reagent, the cells, the composition, or the kit described herein, with the dsRNA reagent, the cells, or the composition as a negative control. The further limitations of the application described below also apply to the efficacy detection method.

[0027] As a preferred embodiment, the RNAi reagent targets human genes.

[0028] As a preferred embodiment, the length of the double-stranded region of the RNAi reagent is 19-30 nucleotide pairs.

[0029] As a further preferred embodiment, the length of the double-stranded region of the RNAi reagent is 19-23 nucleotide pairs.

[0030] As a further preferred embodiment, the length of the double-stranded region of the RNAi reagent is 21 nucleotide pairs.

[0031] This invention yields scramble sequences with minimal off-target effects, which can be used as a negative control group for screening experiments of any target RNAi reagent (such as siRNA). Detailed Implementation

[0032] The following provides a detailed description of specific embodiments of the present invention. It should be understood that the specific embodiments described herein are for illustrative and explanatory purposes only and are not intended to limit the invention. Those skilled in the art can make various modifications and variations to the invention without departing from its scope or spirit. For example, features described or illustrated as part of one embodiment can be used in another embodiment to produce further embodiments.

[0033] Unless otherwise stated, all terms used to disclose this invention (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Further guidance is provided below for a better understanding of the teachings of this invention. The terminology used herein in the specification of this invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0034] The terms “containing,” “comprising,” and “including” as used in this invention are synonyms and are inclusive or open-ended, and do not exclude additional, uncited members, elements, or method steps.

[0035] In this invention, the numerical range represented by endpoints includes all numerical values ​​and fractions contained within that range, as well as the endpoints mentioned.

[0036] This invention relates to concentration values, which include fluctuations within a certain range. For example, fluctuations are allowed within a corresponding precision range. For instance, 2% can fluctuate within ±0.1%. For larger values ​​or values ​​that do not require overly precise control, even greater fluctuations are permitted. For example, 100mM can fluctuate within ranges of ±1%, ±2%, ±5%, etc. Regarding molecular weight, fluctuations of ±10% are allowed.

[0037] In this invention, the terms "multiple" or "various" are used unless otherwise specified, referring to a quantity of 2 or more.

[0038] In this invention, the technical features described in an open-ended manner include both closed-ended technical solutions composed of the listed features and open-ended technical solutions that include the listed features.

[0039] In this invention, terms such as "preferred," "better," "more suitable," and "ideal" are merely descriptions of more effective implementation methods or embodiments, and should be understood not to limit the scope of protection of this invention.

[0040] In this invention, "optionally," "optionally," "optionally," "optionally," "optionally," and "optional" mean that they are optional, that is, they are selected from either "with" or "without." If multiple "optional" or "optional" terms appear in a technical solution, unless otherwise specified and there are no contradictions or mutual constraints, then each "optional" or "optional" term is independent.

[0041] In this invention, the term "dsRNA reagent" refers to "double-stranded RNA," which is an RNAi containing an RNA molecule or molecular complex having a hybrid double-stranded region comprising two antiparallel and substantially complementary nucleic acid strands. In some embodiments of this invention, the dsRNA reagent is scrambled siRNA or a reagent containing scrambled siRNA.

[0042] In this invention, the term "RNAi reagent" (also referred to as "RNAi trigger") means a composition containing RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecules capable of degrading or inhibiting (e.g., under appropriate conditions, degrading or inhibiting) messenger RNA (mRNA) transcripts of a target gene in a sequence-specific manner. As used herein, RNAi reagents may function via RNA interference mechanisms (i.e., by interaction with RNA interference pathways in mammalian cells, such as RNA-induced silencing complexes or RISC) or via any alternative mechanism or pathway. Although it is considered that RNAi reagents function primarily through RNA interference mechanisms as used herein, the disclosed RNAi reagents are not bound to or limited by any particular pathway or mechanism of action. The RNAi reagents disclosed herein consist of a sense strand and an antisense strand, and include, but are not limited to, short (or small) interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), short hairpin RNA (shRNA), and ribonuclease (Dicer) substrates. The antisense strand of the RNAi reagents described herein is at least partially complementary to the mRNA to be targeted. RNAi reagents may include one or more modified nucleotides and / or one or more non-phosphodiester bonds.

[0043] In this invention, "the antisense strand (positive strand) contains at least 15 consecutive nucleotides that differ from the sequence shown in SEQ ID No. X by no more than 3 nucleotides" means that the antisense strand (positive strand) contains at least 15 consecutive nucleotides, and that the at least 15 consecutive nucleotides differ from any of the at least 15 consecutive nucleotides in the sequence shown in SEQ ID No. X by no more than 3 nucleotides. As an example, in some specific embodiments, the antisense strand (positive strand) contains 21 consecutive nucleotides, wherein the sequence of nucleotides 1-15 has one, two, or three nucleotide differences compared to the sequence of nucleotides 2-16 in SEQ ID No. X, and the nucleotides 16-20 in the antisense strand (positive strand) are all identical, partially identical, or all different from the sequence of nucleotides 17-21 in SEQ ID No. X. Such sequences are within the scope of this invention. In some specific embodiments, the antisense strand (positive strand) contains 21 consecutive nucleotides, wherein the sequence of nucleotides 1 to 15 is the same as the sequence of nucleotides 1 to 15 of SEQ ID No. X, and the nucleotides 16 to 21 of the antisense strand (positive strand) are all the same, partially the same, or all different from the sequence of nucleotides 16 to 21 of SEQ ID No. X. Such sequences are also within the scope of the present invention.

[0044] In this invention, the term "at least partially complementary" means that in a hybridization pair of nucleobase or nucleotide sequence molecules, the first oligonucleotide and the second oligonucleotide are partially complementary, substantially complementary, or completely complementary. "Completely complementary" means that in a hybridization pair of nucleobase or nucleotide sequence molecules, all (100%) bases in the adjacent sequence of the first oligonucleotide hybridize with the same number of bases in the adjacent sequence of the second oligonucleotide. The adjacent sequence may comprise all or part of the first or second nucleotide sequence. "Partially complementary" means that in a hybridization pair of nucleobase or nucleotide sequence molecules, at least 70%, but not all, of the bases in the adjacent sequence of the first oligonucleotide hybridize with the same number of bases in the adjacent sequence of the second oligonucleotide. The adjacent sequence may comprise all or part of the first or second nucleotide sequence. "Substantially complementary" means that in a hybridization pair of nucleobase or nucleotide sequence molecules, at least 85%, but not all, of the bases in the adjacent sequence of the first oligonucleotide hybridize with the same number of bases in the adjacent sequence of the second oligonucleotide. The adjacent sequence may contain all or part of the first nucleotide sequence or the second nucleotide sequence.

[0045] In this invention, the term "link" means the combination of two compounds or molecules through a covalent bond. Unless otherwise stated, the term "link" as used herein may refer to a link between a first compound and a second compound, with or without any intermediate atoms or groups of atoms.

[0046] This invention first provides a dsRNA reagent comprising a sense strand and an antisense strand forming a double-stranded region. The antisense strand contains at least 15 (e.g., 15, 16, 17, 18, 19, 20, or 21) consecutive nucleotides differing from the sequence shown in any of SEQ ID No. 1, 2, or 6 by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides. The sense strand contains a nucleotide sequence that is at least partially complementary (e.g., partially complementary, substantially complementary, or completely complementary) to the antisense strand. This invention has found that when the dsRNA reagent has the aforementioned antisense strand, off-target effects are extremely rare, making it suitable as a negative control sequence in RNAi reagent research.

[0047] In some embodiments, the positive strand contains at least 15 (e.g., 15, 16, 17, 18, 19, 20, or 21) consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 7, 8, or 12 by no more than 3 (e.g., 0, 1, 2, or 3) nucleotides.

[0048] In some preferred embodiments, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 7 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 1 by 0, 1, or 2 nucleotides.

[0049] In some preferred embodiments, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 8 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 2 by 0, 1, or 2 nucleotides.

[0050] In some embodiments, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 12 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 6 by 0, 1, or 2 nucleotides.

[0051] In some embodiments, the antisense strand has 15 to 30 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) nucleotides (bases).

[0052] In some embodiments, the positive strand has 15 to 30 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) nucleotides (bases).

[0053] In some specific embodiments, the antisense strand and the sense strand are 19 to 23 nucleotides (bases) in length.

[0054] In this invention, the justice chain and the antisense chain can have the same length or different lengths.

[0055] In some preferred embodiments, both the antisense strand and the sense strand are 21 nucleotides (bases) long.

[0056] In practical implementation, those skilled in the art can combine the sequences provided in this invention by taking into account the complementarity of the sense and antisense strands, thereby obtaining the combined dsRNA reagent.

[0057] The dsRNA reagent of the present invention, without any modification, significantly targets less than or equal to one human gene using its naked sequence (i.e., unmodified sequence). When the antisense strand of the dsRNA reagent contains the sequence shown in SEQ ID No. 1 or SEQ ID No. 2, the naked sequence does not significantly target any human gene, theoretically reaching the ideal scientific threshold boundary. Furthermore, when the antisense strand of the dsRNA reagent contains the sequence shown in SEQ ID No. 2, its effectiveness as a negative control is even better.

[0058] In some specific embodiments, the nucleotide sequence of the sense strand is shown in SEQ ID No. 7, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 1.

[0059] In some specific embodiments, the nucleotide sequence of the sense strand is shown in SEQ ID No. 8, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 2.

[0060] In some specific embodiments, the nucleotide sequence of the sense strand is shown in SEQ ID No. 12, and the nucleotide sequence of the antisense strand is shown in SEQ ID No. 6.

[0061] In some specific embodiments, when the sequence identity between the sense or antisense strand of the dsRNA reagent and the corresponding sequence mentioned in this invention is less than 100% or differs by more than one nucleotide, it still has an effect similar to or equivalent to the corresponding sequence—that is, the number of human genes significantly targeted by the dsRNA reagent is less than or equal to 1, and more preferably, the dsRNA reagent does not significantly target any human gene. In some specific embodiments, two bases such as UU, AA, CC, GG, or UG, or any combination of two nucleic acids, can be added to the 3' end of the antisense strand. Such nucleic acid sequences are also within the scope of protection of this invention.

[0062] In some embodiments, the nucleotides in the dsRNA reagent are each independently unmodified or modified nucleotides. In practice, those skilled in the art can directly use unmodified dsRNA reagents as negative controls, or they can select dsRNA reagents with one or more modified nucleotides as negative controls; such dsRNA reagents are all within the scope of protection of this invention.

[0063] In some embodiments, the modified nucleotide includes one or more of the following: deoxynucleotides, 3'-terminal deoxythymidine (dT) nucleotides, 2'-terminal deoxythymidine (dT) nucleotides, etc. O Methyl-modified nucleotides, 2' Fluorine-modified nucleotides, 2' Deoxy-modified nucleotides, locked nucleotides, unlocked nucleotides, conformation-restricted nucleotides, constrained ethyl nucleotides, base-free nucleotides, 2' Amino-modified nucleotides, 2' O Allyl-modified nucleotides, 2' C Alkyl-modified nucleotides, 2' Hydroxyl-modified nucleotides, 2' Methoxyethyl modified nucleotides, 2' O Alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, non-natural bases including nucleotides, tetrahydropyran-modified nucleotides, 1,5 Nucleotides modified with dehydrated hexitol, nucleotides modified with cyclohexenyl, nucleotides including phosphate thioester groups, nucleotides including methylphosphonate groups, and nucleotides including 5'- Phosphate esters of nucleotides, including 5' Phosphate ester mimicry nucleotides, heat-labile nucleotides, ethylene glycol-modified nucleotides (GNA), nucleotides including 2' phosphate esters, and 2' phosphate esters. O (N Nucleotides modified with methylacetamide.

[0064] In some specific embodiments, the modified site may be at least position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 of the nucleotides of the sense strand and / or antisense strand.

[0065] In some embodiments, the number of human genes significantly targeted by the modified dsRNA reagent (i.e., containing modified nucleotides) is less than or equal to 1, and preferably does not significantly target any human genes.

[0066] In some embodiments, the length of the double-stranded region is 19 to 30 nucleotide pairs.

[0067] In some preferred embodiments, the length of the double-stranded region is 19 to 23 nucleotide pairs.

[0068] As an example, in some specific implementations, the length of the double-stranded region can be 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotide pairs.

[0069] In some preferred embodiments, the length of the double-stranded region is 21 nucleotide pairs.

[0070] In some embodiments, at least one of the sense and antisense strands is attached to one or more ligands selected from the following: lectins, glycoproteins, lipids, aptamers, polymers, polypeptides, proteins, lipophilic molecules, polysaccharides, vitamins, antibodies or antibody fragments, light-sensitive oligonucleotides (OliP), lipid nanoparticles (LNPs), exosomes, metal nanoparticles, polymer nanoparticles, viral vectors, and haptens.

[0071] In some specific embodiments, the ligand is selected from one or more of the following: thyroid-stimulating hormone, melanocyte-stimulating hormone, lectin, glycoprotein, nucleic acid aptamer, surfactant protein A, mucin carbohydrate, polyvalent lactose, polyvalent galactose, N... Acetyl Galactosamine or its derivatives, N Acetyl Glucosamine polymannose, polyfucose, glycosylated polyamino acids, polygalactose, transferrin, TfR antibody, bisphosphonates, polyglutamic acid esters, polyaspartic acid esters, lipids, cholesterol, steroids, bile acids, folic acid, vitamin B12, biotin, RGD peptides or their analogues.

[0072] In some specific embodiments, the ligand is selected from one or more of the following: N Acetylgalactosamine or its derivatives, lipid nanoparticles, RGD peptides or their analogs, TfR antibodies, nucleic acid aptamers, folic acid, transferrin, ionizable lipids, cholesterol or its derivatives, polygalactose, and polylactose.

[0073] In some specific embodiments, the ligand includes: one or more N Acetylgalactosamine (GalNAc), and / or one or more N Acetylgalactosamine (GalNAc) derivative.

[0074] In some embodiments, the ligand is attached to the 3' or 5' end of the sense or antisense strand of the nucleic acid.

[0075] Based on common knowledge in the field regarding the need for control in RNAi reagents under study, the dsRNA reagent (scramble siRNA) of the present invention has excellent negative control effects when applied to different targeted drug delivery systems.

[0076] The present invention further provides a cell containing the dsRNA reagent described above.

[0077] In some embodiments, the cells can be used for purposes such as gene function research, disease model research, or drug screening.

[0078] In some embodiments, the cells do not develop into an animal individual. In some specific embodiments, the cells may be microbial cells or animal cells (including human cells), but the animal cells are not animal embryonic stem cells or cells at various stages of formation and development (e.g., germ cells, fertilized egg cells, etc.).

[0079] The present invention further provides a composition comprising the dsRNA reagent and a pharmaceutically acceptable carrier.

[0080] The composition can be prepared using conventional methods from the dsRNA reagent and the pharmaceutically acceptable carrier to serve as a negative control for the corresponding RNAi formulation under investigation. For example, the composition can be an injection solution. The injection solution can be used for subcutaneous, intramuscular, or intravenous injection.

[0081] The present invention further provides a kit containing the dsRNA reagent, the cells, or the composition described herein.

[0082] In practice, the dsRNA reagent, the cells, or the composition can be provided in the kit using one or a combination of reagents.

[0083] The present invention further provides the application of the dsRNA reagent, the cells, or the composition described herein as a negative control in the field of RNA interference.

[0084] In some implementations, the RNA interference targets human genes.

[0085] The present invention further provides the application of the dsRNA reagent, the cells, the composition, or the kit in the detection of the efficacy of RNAi reagents, wherein the dsRNA reagent, the cells, or the composition are used as negative controls.

[0086] That is, the present invention also provides a method for detecting the efficacy of an RNAi reagent, the method comprising: using the dsRNA reagent, the cells, the composition, or the kit described herein, with the dsRNA reagent, the cells, or the composition as a negative control. The further limitations of the application described below also apply to the efficacy detection method.

[0087] In some embodiments, the RNAi reagent targets human genes.

[0088] In some embodiments, the length of the double-stranded region of the RNAi reagent is 19 to 30 nucleotide pairs.

[0089] In some preferred embodiments, the length of the double-stranded region of the RNAi reagent is 19 to 23 nucleotide pairs.

[0090] As an example, in some specific implementations, the length of the double-stranded region can be 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotide pairs.

[0091] In some specific embodiments, the RNAi reagent is siRNA or a reagent containing siRNA.

[0092] In some preferred embodiments, the length of the double-stranded region is 21 nucleotide pairs.

[0093] In specific implementation, those skilled in the art can apply the dsRNA reagent of the present invention or products containing the dsRNA reagent to various basic research and practical application development of RNA interference, such as off-target effect assessment, silencing effect assessment, cytotoxicity testing, signaling pathway research, development and screening of RNAi drugs, gene function research, immune response research, and gene expression analysis. Such applications are all within the protection scope of the present invention.

[0094] The embodiments of the present invention will be described in detail below with reference to examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. For experimental methods in the following embodiments where specific conditions are not specified, please refer to the guidelines given in this invention, or follow experimental manuals or conventional conditions in the art, or other experimental methods known in the art, or follow the conditions recommended by the manufacturer.

[0095] In the specific embodiments described below, the measurement parameters involving raw material components may have slight deviations within the weighing accuracy range unless otherwise specified. Temperature and time parameters are subject to acceptable deviations due to instrument testing accuracy or operational precision.

[0096] I. Experimental Methods 1. Cell transfection assay: Recovery and maintenance culture of H1975 cells (1) Cell recovery: 1) Remove H1975 cells from the liquid nitrogen tank and quickly place them in a 37°C water bath. Gently shake the cells to allow the liquid in the cryovial to thaw completely (this takes about 2 minutes). Avoid letting the water submerge the cap during shaking to prevent contamination. 2) Sterilize the outer surface of the cryovial with 75% alcohol, and then transfer the cells in the cryovial to a centrifuge tube containing 9 mL of complete culture medium (RPMI 1640 + 10% FBS) in a laminar flow hood. Centrifuge at 1000 rpm for 5 min. 3) After centrifugation, discard the supernatant, resuspend in 10 mL of complete culture medium, transfer to a 10 cm dish, and then incubate in a 37℃ / 5% CO2 incubator.

[0097] (2) Cell maintenance culture: 1) When the confluence of cells in the culture dish reaches 80%-90%, discard the culture medium, wash once with 5mL DPBS (supplier: Gibco, catalog number: 14190144), then add 1mL of 0.25% trypsin and incubate at 37℃ for about 2-3 minutes to digest. 2) After digestion, the cells have basically detached from the culture dish. Then, add 5 mL of complete culture medium to stop the digestion, mix well by pipetting and aspiration, and transfer to a 15 mL centrifuge tube. Centrifuge at 1000 rpm for 5 min. 3) Discard the supernatant after centrifugation, resuspend the cell pellet in 5 mL of complete culture medium, mix well, take a small amount of cell suspension for cell counting, then passage and plate according to experimental needs, and incubate in a 37℃ / 5% CO2 incubator.

[0098] (3) Cell cis-transfection steps: 1) The day before transfection, plate the cells and digest them in a 10cm dish. First, remove the culture medium, wash once with 5mL DPBS, then add 1mL of 0.25% trypsin and incubate at 37℃. When the cells detach from the dish, add 5mL of complete culture medium to stop the digestion. Transfer the digested cells to a 15mL centrifuge tube and centrifuge at 1000rpm for 5min. Remove the supernatant, resuspend the cells in 5mL of complete culture medium, take 30μL of the cell suspension and count the viable cells using trypan blue. Then, plate the cells according to the number of viable cells, 500,000 cells per well in a 6-well plate. 2) For transfection, prepare two sterile, DNase / RNase-free 1.5 mL centrifuge tubes for each well of a 6-well plate, designated as tubes A and B. Add 125 μL of Opti-MEM to each tube, then add 2.5 pmol siRNA to tube A and 7.5 μL of RNAiMAX reagent to tube B. After mixing the liquid in tube A, transfer it to tube B, gently pipette to mix, and incubate at room temperature for 5 min. 3) Add the mixture from step 2) to the 6-well plate from step 1), 250 μL per well, to make the final concentration of siRNA 1 nM. Then, place the 6-well plate in an incubator and continue to incubate for 48 h. The experimental control group only added RNAiMAX reagent. The siRNA transfection group and the control group each performed three biological replicates.

[0099] 2. Cell RNA Extraction Steps The following procedures were all performed in an RNase-free environment (Reagent name: FastPure Cell / TissueTotal RNA Isolation Kit V2, Catalog number: RC112-01).

[0100] 1) After digesting the transfected cells cultured for 48 h, transfer them to a 1.5 mL centrifuge tube, centrifuge, remove the supernatant, add 500 μL Buffer RL, mix by pipetting, and let stand at room temperature for 5 min to fully lyse the cells. 2) Transfer the lysed sample to FastPure gDNA-Filter Columns III (FastPure gDNA-Filter Columns III is already in the collection tube), and centrifuge at 12,000 rpm for 30 seconds. Discard the FastPure gDNA-Filter Columns III and collect the filtrate; 3) Add 250 μL of anhydrous ethanol to the filtrate and mix thoroughly; 4) Transfer all the mixture from step 3) to FastPure RNA Columns III (FastPure RNA Columns III has been placed in the collection tube), centrifuge at 12,000 rpm for 30 seconds, and discard the filtrate; 5) Add 700 μL of Buffer RW1 to FastPure RNA Columns Ⅲ, centrifuge at 12,000 rpm for 30 seconds, and discard the filtrate; 6) Add 700 μL of Buffer RW2 (with anhydrous ethanol added) to FastPure RNA Columns Ⅲ, centrifuge at 12,000 rpm for 30 sec, and discard the filtrate; 7) Add 500 μL of Buffer RW2 (with anhydrous ethanol added) to FastPure RNA Columns Ⅲ, centrifuge at 12,000 rpm for 2 min, and carefully remove the adsorption column from the collection tube to avoid contact with the filtrate and contamination. 8) Discard the filtrate, put FastPure RNA Columns Ⅲ back into the collection tube, and centrifuge at 12,000 rpm for 1 min to prevent ethanol contamination; 9) Carefully transfer the adsorption column to a new RNase-free Collection Tube 1.5 mL centrifuge tube. Add 50 μL of ribonuclease-free ddH₂O (preheated to 37°C) dropwise to the center of the column. Incubate at room temperature for 2 min, then centrifuge at 12,000 rpm for 1 min to elute RNA. The extracted total RNA can be used directly for downstream experiments or stored at -85 to -65°C.

[0101] 3. Construction of RNA-Seq libraries mRNAs were screened and libraries were constructed using Yeasen's mRNA library preparation kit (12309ES24).

[0102] (1) mRNA purification and fragmentation 1) Remove the mRNA Capture Beads from 2-8℃ and let them stand to allow their temperature to equilibrate to room temperature for about 30 minutes.

[0103] 2) Prepare a nuclease-free centrifuge tube, take 10 ng-4 μg of total RNA, add nuclease-free water to make up the volume to 50 μL, and place on ice for later use.

[0104] 3) Invert or vortex to mix the magnetic beads. Add 50 μL of the magnetic bead suspension to 50 μL of total RNA sample and pipette six times to mix thoroughly.

[0105] 4) Place the mixture of magnetic beads and RNA in a PCR instrument and incubate at 65°C for 5 min; 25°C for 5 min; 25°C, hold, to complete the binding of RNA with the capture magnetic beads.

[0106] 5) Place the sample in a magnetic rack and let it stand at room temperature for 5 minutes to separate the mRNA from the total RNA. Carefully remove the supernatant.

[0107] 6) Remove the sample from the magnetic rack, resuspend the magnetic beads in 200 μL Beads Wash Buffer, and pipette repeatedly 6 times to thoroughly mix. Place the sample in the magnetic rack and let it stand at room temperature for 5 min, then carefully remove the supernatant.

[0108] 7) Repeat step 6), washing twice in total.

[0109] 8) Remove the sample from the magnetic rack, add 50 μL of Tris Buffer to resuspend the magnetic beads, and pipette repeatedly 6 times to mix thoroughly.

[0110] 9) Place the sample in the PCR instrument, 80℃ for 2 min; 25℃, hold, to wash out the mRNA.

[0111] 10) Remove the sample from the PCR instrument, add 50 μL of Beads Binding Buffer, and mix thoroughly by pipetting 6 times.

[0112] 11) Place at room temperature for 5 min to allow the mRNA to bind to the magnetic beads.

[0113] 12) Place the sample in a magnetic rack and let it stand at room temperature for 5 minutes. Carefully remove the supernatant.

[0114] 13) Remove the sample from the magnetic rack, resuspend the magnetic beads in 200 μL Beads Wash Buffer, and pipette repeatedly 6 times to mix thoroughly. Place the sample back into the magnetic rack, let it stand at room temperature for 5 min, and aspirate all the supernatant.

[0115] 14) Remove the sample from the magnetic rack, resuspend the magnetic beads in 18.5 μL Frag / Prime Buffer, and mix thoroughly by pipetting 6 times; place the sample in a PCR instrument (preset to 94℃) for mRNA fragmentation, the procedure of which is shown in Table 1.

[0116] Table 1 mRNA fragmentation procedure

[0117] 15) After the fragmentation process is complete, to prevent poly(A) tail RNA from binding to magnetic beads, immediately place the sample in a magnetic rack. After the solution becomes clear, transfer 17 μL of supernatant to a new nuclease-free centrifuge tube and immediately begin the synthesis of first-strand cDNA.

[0118] (2) Synthesis of first-strand cDNA 1) Remove the first-strand synthesis reagent from -20℃, invert to mix, and then briefly incubate. Prepare the reaction solution for first-strand cDNA synthesis as shown in Table 2.

[0119] Table 2 First-strand cDNA Synthesis Reaction System

[0120] 2) Use a pipette to gently mix the mixture, then centrifuge the reaction solution to the bottom of the tube.

[0121] 3) Place the PCR tubes in a PCR instrument and set the reaction program as shown in Table 3 to synthesize the first-strand cDNA. Immediately after the reaction is complete, synthesize the second-strand cDNA.

[0122] Table 3. First-strand cDNA synthesis reaction procedure

[0123] (3) Synthesis of second-strand cDNA / end repair / addition of A 1) Remove the second-strand synthesis reagent from -20 ℃, thaw it, and mix it by inverting. Prepare the second-strand cDNA synthesis / end repair / A addition reaction solution as shown in Table 4.

[0124] Table 4 Second-strand cDNA Synthesis Reaction System

[0125] 2) Use a pipette to gently mix the mixture, then centrifuge the reaction solution to the bottom of the tube.

[0126] 3) Place the PCR tubes into the PCR instrument and set the reaction program as shown in Table 5 to synthesize the second-strand cDNA.

[0127] Table 5. Second-strand cDNA synthesis reaction procedure

[0128] (4) Adapter Ligation This step allows for the attachment of specific Illumina® connectors to the ends of the product after end repair and dA tail addition.

[0129] 1) Dilute the adapter to an appropriate concentration based on the amount of input RNA.

[0130] 2) Thaw each reagent in Table 6, invert and mix well, and place on ice for later use.

[0131] 3) Continue to prepare the reaction system shown in Table 6 in the PCR tube for the synthesis of second-strand cDNA.

[0132] Table 6 Connector Connection System

[0133] 4) Use a pipette to gently mix the mixture and briefly centrifuge to collect the reaction solution to the bottom of the tube.

[0134] 5) Place the PCR tube in the PCR instrument and set the reaction program shown in Table 7 to perform the adapter ligation reaction: Table 7 Connector Connection Response Procedure

[0135] (5) Clean Up Post Ligation The target length library is obtained through purification and sorting.

[0136] 1) Vortex oscillation or fully inverting the magnetic beads to ensure uniform mixing.

[0137] 2) According to the DNA fragment length requirements, add 20 μL (0.20×) of the first round of sorting magnetic beads to the above 100 μL adapter ligation system, and mix by vortexing or pipetting 10 times. Incubate at room temperature for 10 min.

[0138] 3) Briefly centrifuge the PCR tube and place it in a magnetic rack. After the solution has clarified (about 5 min), carefully transfer 100 μL of supernatant into a clean centrifuge tube.

[0139] 4) Add 10 μL (0.10×) of the second round of sorting magnetic beads to the top cleaning.

[0140] 5) Vortex or pipette 10 times to mix, then let stand at room temperature for 10 minutes.

[0141] 6) Briefly centrifuge the PCR tube and place it in a magnetic rack. After the solution becomes clear (about 3 minutes), carefully remove the supernatant.

[0142] 7) Keep the PCR tube in the magnetic rack at all times, add 200 μL of freshly prepared 80% ethanol to rinse the magnetic beads, incubate at room temperature for 30 seconds, and carefully remove the supernatant.

[0143] 8) Repeat step 7).

[0144] 9) Keep the PCR tube in the magnetic rack at all times, and open the lid to dry the magnetic beads until they just start to crack (about 3 minutes).

[0145] 10) Remove the PCR tube from the magnetic rack, add 21 μL ddH2O, vortex or gently pipette to mix thoroughly, and let stand at room temperature for 5 min.

[0146] 11) Briefly centrifuge the PCR tube and place it in a magnetic rack to separate the magnetic beads and liquid. After the solution has clarified (about 3 min), carefully transfer 20 μL of supernatant into a clean tube.

[0147] (6) Library Amplification This step involves PCR amplification and enrichment of the purified or length-sorted adapter ligation products.

[0148] 1) Thaw the reagents in Table 8, invert and mix them, and place them on ice for later use.

[0149] 2) Prepare the reaction system shown in Table 8 in a sterile PCR tube.

[0150] Table 8 PCR reaction system for long connector ligation products

[0151] 3) Use a pipette to gently blow or shake to mix, and briefly centrifuge to collect the reaction solution to the bottom of the tube.

[0152] 4) Place the PCR tube in the PCR instrument, set the reaction program shown in Table 9, and perform PCR amplification.

[0153] Table 9 PCR Amplification Reaction Procedure

[0154] (7) Clean Up Post Amplification (CPA) of Amplified Products 1) Preparation: Remove the Hieff NGS® DNA Selection Beads from the refrigerator and allow them to equilibrate at room temperature for at least 30 minutes. At the same time, prepare 80% ethanol.

[0155] 2) Vortex oscillation or fully inverting the magnetic beads to ensure thorough mixing.

[0156] 3) Add 45 μL of Hieff NGS® DNA Selection Beads (0.9×, Beads:DNA=0.9:1) to the amplification product, vortex or pipette to mix, and incubate at room temperature for 5 min.

[0157] 4) Briefly centrifuge the PCR tube and place it in a magnetic rack to separate the magnetic beads and liquid. After the solution becomes clear (about 5 min), carefully remove the supernatant.

[0158] 5) Keep the PCR tube in the magnetic rack at all times, add 200 μL of freshly prepared 80% ethanol to rinse the magnetic beads, incubate at room temperature for 30 seconds, and then carefully remove the supernatant.

[0159] 6) Repeat step 5), rinsing a total of two times.

[0160] 7) Keep the PCR tube in the magnetic rack at all times, and open the lid to air dry the magnetic beads until they just start to crack (no more than 5 minutes).

[0161] 8) Remove the PCR tube from the magnetic rack, add 21 μL of ddH2O, vortex or gently pipette until fully mixed, and let stand at room temperature for 5 min. Briefly centrifuge the PCR tube and place it on the magnetic rack to stand until the solution becomes clear (about 3 min). Carefully transfer 20 μL of supernatant to a new PCR tube for library quantification and quality control.

[0162] 4. Statistical analysis of RNA-Seq data (1) Use Trimmomatic (v0.39) to perform quality control on the offline data and obtain Clean_data.

[0163] (2) Use Hisat2 (v2.2.1) to compare the quality-controlled clean_data with the reference genome GRCh38.

[0164] (3) Use FeatureCounts (v2.0.3) to compare the results and calculate the expression levels of the transcriptome.

[0165] (4) Use rnanorm (v1.5.1) to convert count to TPM.

[0166] (5) Differential analysis was performed using the DESeq2 package (v1.42.1) in R software (v4.3.1). The p-value was calculated using the Wald test, and the Benjamini-Hochberg test was used for correction. The condition for differentially expressed genes was: padj < 0.05 & abs(log2FoldChange) >= 2.

[0167] II. Experimental Results 1. Candidate scramble siRNA sequences The six candidate scramble siRNA sequences selected are shown in Table 10.

[0168] Table 10 Six candidate scramble siRNA sequences

[0169] 2. RNA-Seq data analysis results: Compared with the control group, the DESeq2 significance difference analysis was performed on the RNA-Seq data mediated by 6 scramble siRNA sequences. Among them, the criteria of P-adj<0.05&|log2Foldchange|>2 were met. (This criterion is derived from the following three articles: Conesa A, Madrigal P, Tarazona S, et al. A survey of bestpractices for RNA-seq data analysis[J]. Genome biology, 2016, 17: 1-19.;LoveMI, Huber W, Anders S. Moderated estimation of fold change and dispersionfor RNA-seq data with DESeq2[J]. Genome biology, 2014, 15: 1-21.;Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing[J]. Journal of the Royal Statistical Society: series B (Methodological), 1995, 57(1): Genes with values ​​of 289-300 are considered to be significantly off-target genes. See Table 11 below for detailed statistical results.

[0170] Table 11 Summary of significant off-target gene information mediated by Scramble siRNA

[0171] The above tables were compiled and summarized, and the detailed results are shown in Table 12 below. Specifically, the scramble siRNA sequences NWSC-1 and NWSC-2 did not significantly target any genes; NWSC-6 targeted only one gene. NWSC-3, NWSC-4, and NWSC-5, however, targeted 10, 35, and 88 genes, respectively.

[0172] Table 12

[0173] Conclusion: The NWSC-1, NWSC-2, and NWSC-6 sequences can be used as negative control sequences in studies related to human siRNA.

[0174] The above-described embodiments are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of protection of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.

Claims

1. A dsRNA reagent comprising a sense strand and an antisense strand forming a double-stranded region, wherein, The antisense strand contains at least 15 consecutive nucleotides that differ from any of the sequences shown in SEQ ID No. 1, 2, and 6 by no more than 3 nucleotides; The sense strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.

2. The dsRNA reagent according to claim 1, wherein, The positive strand contains at least 15 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 7, 8, or 12 by no more than 3 nucleotides.

3. The dsRNA reagent according to claim 1, wherein, The sense strand contains at least 16, 17, 18, 19, or 20 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 7, 8, or 12 by no more than 3 nucleotides, and the antisense strand contains at least 16, 17, 18, 19, or 20 consecutive nucleotides that differ from the sequence shown in any of SEQ ID No. 1, 2, or 6 by no more than 3 nucleotides.

4. The dsRNA reagent according to claim 1, wherein, The sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 7 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 1 by 0, 1, or 2 nucleotides. Alternatively, the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 8 by 0, 1, or 2 nucleotides, and the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID No. 2 by 0, 1, or 2 nucleotides; Alternatively, the sense strand may contain a nucleotide sequence that differs from the sequence shown in SEQ ID No. 12 by 0, 1, or 2 nucleotides, and the antisense strand may contain a nucleotide sequence that differs from the sequence shown in SEQ ID No. 6 by 0, 1, or 2 nucleotides.

5. The dsRNA reagent according to claim 1, wherein, The nucleotide sequence of the sense strand is shown in SEQ ID No. 7, and the nucleotide sequence of the antisense strand is shown in SEQ ID No.

1.

6. The dsRNA reagent according to claim 1, wherein, The nucleotide sequence of the sense strand is shown in SEQ ID No. 8, and the nucleotide sequence of the antisense strand is shown in SEQ ID No.

2.

7. The dsRNA reagent according to claim 1, wherein, The nucleotide sequence of the sense strand is shown in SEQ ID No. 12, and the nucleotide sequence of the antisense strand is shown in SEQ ID No.

6.

8. The dsRNA reagent according to any one of claims 1 to 7, wherein, The nucleotides in the dsRNA reagent are each independently unmodified or modified nucleotides; The modified nucleotides include one or more of the following: deoxynucleotides, 3'-terminal deoxythymidine nucleotides, 2'-terminal deoxythymidine nucleotides, etc. O Methyl-modified nucleotides, 2' Fluorine-modified nucleotides, 2' Deoxy-modified nucleotides, locked nucleotides, unlocked nucleotides, conformation-restricted nucleotides, constrained ethyl nucleotides, base-free nucleotides, 2' Amino-modified nucleotides, 2' O Allyl-modified nucleotides, 2' C Alkyl-modified nucleotides, 2' Hydroxyl-modified nucleotides, 2' Methoxyethyl modified nucleotides, 2' O Alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, non-natural bases including nucleotides, tetrahydropyran-modified nucleotides, 1,5 Nucleotides modified with dehydrated hexitol, nucleotides modified with cyclohexenyl, nucleotides including phosphate thioester groups, nucleotides including methylphosphonate groups, and nucleotides including 5'- Phosphate esters of nucleotides, including 5' Phosphate ester mimicry nucleotides, heat-labile nucleotides, ethylene glycol-modified nucleotides, nucleotides including 2' phosphate esters, and 2' phosphate esters. O (N Nucleotides modified with methylacetamide.

9. The dsRNA reagent according to any one of claims 1 to 8, wherein, The length of the double-stranded region is 19 to 30 nucleotide pairs; more preferably 19 to 23 nucleotide pairs.

10. The dsRNA reagent according to claim 9, wherein, The length of the double-stranded region is 21 nucleotide pairs.

11. The dsRNA reagent according to any one of claims 1 to 10, wherein, At least one of the sense and antisense strands is attached to one or more ligands selected from the following: lectins, glycoproteins, lipids, nucleic acid aptamers, polymers, polypeptides, proteins, lipophilic molecules, polysaccharide molecules, vitamins, antibodies or antibody fragments, photosensitive oligonucleotides, lipid nanoparticles, exosomes, metal nanoparticles, polymer nanoparticles, viral vectors, and haptens.

12. The dsRNA reagent according to claim 11, wherein, The ligand is selected from one or more of the following: N Acetylgalactosamine or its derivatives, lipid nanoparticles, RGD peptides or their analogs, TfR antibodies, nucleic acid aptamers, folic acid, transferrin, ionizable lipids, cholesterol or its derivatives, polygalactose, and polylactose.

13. A cell containing the dsRNA reagent according to any one of claims 1 to 12.

14. A composition comprising the dsRNA reagent of any one of claims 1 to 12 and a pharmaceutically acceptable carrier.

15. A kit comprising the dsRNA reagent of any one of claims 1 to 12, the cells of claim 13, or the composition of claim 14.

16. The use of the dsRNA reagent of any one of claims 1 to 12, the cell of claim 13, or the composition of claim 14 as a negative control in the field of RNA interference.

17. The use of the dsRNA reagent of any one of claims 1 to 12, the cell of claim 13, the composition of claim 14, or the kit of claim 15 in the detection of the effect of RNAi reagents, wherein, The dsRNA reagent, the cells, or the composition were used as negative controls.

18. The application according to claim 17, wherein, The RNAi reagent targets human genes.

19. The application according to claim 17 or 18, wherein, The length of the double-stranded region of the RNAi reagent is 19-30 nucleotide pairs; more preferably 19-23 nucleotide pairs; and even more preferably 21 nucleotide pairs.